Cardiovascular Medicines Articles & Analysis: Older
23 news found
(NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, has initiated the first-ever prospective coronary intervention study consisting of all female patients – EMPOWER CAD – to determine whether the positive results from earlier coronary IVL studies with the Shockwave C2 Coronary IVL ...
The Cardiovascular Research Foundation (CRF) is pleased to announce that Puzzle Medical Devices Inc. has won the TCT 2022 Shark Tank Innovation Competition for its novel circulatory support device that is implanted percutaneously in the abdominal aorta. The competition took place during Transcatheter Cardiovascular Therapeutics (TCT), the world’s premier ...
Villines will be leading clinical strategy development and execution for Elucid’s commercial and in-development products. A distinguished professor of medicine, clinical cardiologist, and researcher focused on cardiovascular imaging and prevention, Dr. Villines is board-certified in internal medicine, cardiovascular ...
ByElucid
We look forward to working with R-One on a daily basis to benefit more patients and doctors,” commented Professor Jian An, department of cardiovascular medicine, dean of Shanxi Cardiovascular Hospital. “R-One drastically improves our working conditions. ...
ByRobocath
– February 15, 2022 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced completion of enrollment in the BIOADAPTOR randomized controlled trial (RCT). ...
(Nasdaq: BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CardiAMP® Cell Therapy System for the treatment of heart failure. ...
Brian Davis named Chief Financial Officer XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today announced that it has appointed Elizabeth Tarka, M.D. as Chief Medical Officer and A. ...
CAC is a recognized vital biomarker for detection of cardiovascular disease. Nanox.AI believes that early detection and subsequent treatment of cardiovascular disease has the potential to significantly decrease the morbidity and mortality of this highly prevalent condition. ...
There is now an abundance of published literature on atherosclerosis which has long defined lipid-rich necrotic core as the major culprit for cardiovascular disease progression that leads to myocardial ischemia and acute events. “Obtaining reimbursement for providers to identify key biomarkers of arterial narrowing and plaque stability will advance the field of ...
ByElucid
Xeltis has the most advanced restorative technology platform in cardiovascular medicine and may positively impact millions of lives.” Xeltis’ devices are vascular grafts and heart valves designed to turn into living valves and vessels by harnessing the body’s natural healing process and by facilitating tissue formation once implanted. ...
Cardiac Dimensions, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the launch of the U.S. pivotal study The EMPOWER Trial. ...
Xeltis, a clinical-stage company with the most advanced polymer-based restorative cardiovascular devices, today announced that it has started the first-ever pivotal trial for a synthetic restorative pulmonary valve. ...
Azadeh Beheshtian, board certified in cardiovascular disease and internal medicine by the American Board of Internal Medicine. ...
The promise of this work is to enable true precision medicine for cardiovascular disease. There have been numerous advancements in the world of cardiovascular therapeutics over the past decades, including development of intensive lipid-lowering agents such as PCSK9 inhibitors and anti-inflammatory therapies such as canakinumab. ...
ByElucid
He joins co-principal investigators Gregg Stone, MD, of New York’s Mount Sinai Health System and Andrew Wechsler, MD, of Philadelphia’s Drexel University College of Medicine in overseeing the trial. Dr. Estep specializes in managing advanced heart failure patients and is the Head of the Section of Heart Failure and Transplantation in the Tomsich Family Department of ...
About Cardiac Dimensions Cardiac Dimensions is a leader in the development of innovative, minimally invasive treatments to address heart failure and related cardiovascular conditions. Privately held, the company’s lead investors include Aperture Venture Partners, Arboretum Ventures, HostPlus, Life Sciences Partners, Lumira Ventures and M.H. ...
Marc Hirschvogel, CEO of Hirschvogel Vermögensverwaltung GmbH, and continued:“Having expertise in this field, due to my background in computational mechanics and engineering in cardiovascular medicine, I am convinced that this non-blood-contacting device will set a key milestone in treatment of advanced heart failure and gives engineers room for more ...
Tardif, a renowned cardiologist and director of the MHI Research Center, has made significant contributions in the field of atherosclerosis and other cardiovascular diseases. He holds the Canada Research Chair in personalized medicine and the University of Montreal Pfizer-endowed research chair in atherosclerosis, and his research includes efforts on the ...
“With Aortix, we have a device innovation that truly warrants breakthrough designation for the treatment of ADHF patients with worsening renal function, a particularly challenging group of patients for whom outcomes are generally poor and treatment options limited,” commented Keith Aaronson, MD, MS, Pitt Collegiate Professor of Cardiovascular Medicine ...
Abraham makes this move to V-Wave after more than 16 years as Director of the Division of Cardiovascular Medicine at the Ohio State University. Dr. Abraham has vast clinical trial experience with drugs and devices for heart failure. ...